Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 2 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 8 |
| Key Opinion Leaders: A History | 7 | 1 |
| Established KOL Roles in Drug Discovery, Development and Marketing | 8 | 2 |
| The Changing Environment for the Pharmaceutical Industry | 10 | 1 |
| Market Access: Reimbursement Authorities | 10 | 1 |
| Market Access: Purchasing | 11 | 1 |
| Generic and Specialty Medicines | 11 | 1 |
| Emerging Markets | 12 | 1 |
| Big Data: the Changing Environment for Science and Medicine | 13 | 1 |
| Emerging Business Models | 13 | 1 |
| Emerging KOL Roles | 14 | 1 |
| Building Relationships for External Innovation | 15 | 8 |
| Introduction | 15 | 1 |
| Growth Close to Hubs and Clusters | 15 | 1 |
| Working with Academia | 16 | 1 |
| Pfizer s Centers for Therapeutic Innovation | 17 | 1 |
| The California Institute for Biomedical Research | 18 | 1 |
| New Funding Models to Support Innovation | 18 | 1 |
| Drug Development Relationships | 19 | 1 |
| Key Opinion Leaders in the Emerging Drug Discovery and Development Landscape: Finding Experts | 19 | 1 |
| Knode | 20 | 1 |
| Key Opinion Leaders in the Emerging Drug Discovery and Development Landscape: Building Relationships | 21 | 1 |
| Conclusions | 22 | 1 |
| Building Relationships with Healthcare Professionals | 23 | 12 |
| Introduction | 23 | 1 |
| Identifying KOLs and Building Relationships | 24 | 1 |
| KOL Management | 25 | 1 |
| Healthcare Engagement: Codes of Practice | 26 | 1 |
| US | 26 | 1 |
| The Office of Inspector General Guidelines | 27 | 1 |
| The Pharmaceutical Research and Manufacturers Association Codes of Practice | 27 | 2 |
| EU | 29 | 1 |
| KOLs in Emerging Markets | 30 | 1 |
| Emerging Markets: Compliance Environment | 30 | 1 |
| Key Opinion Leaders Online | 30 | 1 |
| Examples of Best Practice in Digital Engagement | 31 | 1 |
| Channels for Engaging Healthcare Professionals Online | 32 | 1 |
| Digital Literacy | 32 | 1 |
| Regulating online engagement | 33 | 1 |
| Evolution of KOL Interactions | 34 | 1 |
| Building Relationships with Patients | 35 | 10 |
| Introduction | 35 | 1 |
| Patients Roles in Drug Development | 35 | 2 |
| Overcoming Barriers to Effective Engagement | 37 | 1 |
| Increasing Patients Awareness of the Clinical Research Process | 37 | 1 |
| Ethical Principles for Working with Patients | 37 | 1 |
| Transparency | 38 | 1 |
| Gaining Insights from Patients | 38 | 1 |
| Patients Online | 39 | 1 |
| Working with Online Patient Communities | 40 | 1 |
| PatientsLikeMe.com | 40 | 1 |
| CureTogether.com | 41 | 1 |
| Patient Intelligence | 42 | 1 |
| PIP Health | 42 | 1 |
| Clinical Trial Recruitment | 43 | 1 |
| Venture Philanthropy | 43 | 1 |
| Conclusions | 44 | 1 |
| Appendix | 45 | 5 |
| Abbreviations | 45 | 1 |
| References | 45 | 3 |
| Research Methodology | 48 | 2 |
| Coverage | 48 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 49 | 1 |
| Expert Panel Validation | 49 | 1 |
| Contact Us | 49 | 1 |
| Disclaimer | 49 | 1 |